ABCL

AbCellera Biologics (ABCL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Earnings

AbCellera Prepares Longer-Lasting Hot-Flash Drug To Get Ahead Of Potential Competitors

The successor could mean fewer injections and lower production costs, while the lead treatment remains on track for late-stage testing.

SEC Filings

AbCellera Narrows Loss To $40.8 Million From $57.1 Million As Research Spending Falls

The antibody developer currently plans to stop ABCL575 after early-stage testing, even though the study met its goals.